Maternal infection is an environmental risk factor for both schizophrenia and autism (
Brown and Susser, 2002;
Patterson, 2002). The lack of evidence for direct infection of the fetus (
Shi et al., 2005) (but see
Aronsson et al., 2002), and the fact that multiple pathogens cause similar results in humans [e.g., influenza (
Brown, 2006), herpes (
Babulas et al., 2006), rubella (
Chess, 1977)], indicates that MIA, in general, is detrimental to the developing brain. The data presented here confirms previous reports (see Introduction) that MIA causes behavioral and gene-expression changes in the offspring of pregnant mice. When IL-6 is eliminated from the maternal immune response using genetic methods or with blocking antibodies, however, the behavioral deficits associated with MIA are not present in the adult offspring. Antibodies to IL-1
β or IFN
γ did not prevent behavioral deficits, suggesting that the anti-IL-6 effect is specific. Furthermore, maternal exposure to IL-6, in the absence of poly(I:C) or infection, is sufficient to cause two key deficits in the adult offspring, PPI and LI disruption. Thus, IL-6 is central to the process by which MIA causes long-term behavioral alterations in the offspring.
We also show that blocking IL-6 eliminates virtually all of the transcriptional changes caused by MIA. The microarray data presented here are essentially numerical data that estimate the extent to which treatment with the anti-IL-6 antibody is able to normalize changes in expression. Our sole aim in including the numerical data here is to demonstrate that blocking IL-6 prevents >90% of the changes seen in offspring of poly(I:C)-injected females, showing that gene expression changes, as well as behavioral changes, are normalized by eliminating IL-6 from the maternal immune response.
Poly(I:C) signals through Toll-like receptor 3 via a nuclear factor
κB-dependent mechanism (
Alexopoulou et al., 2001). Although usually cited for its ability to induce interferons (
Toth et al., 1990;
Katafuchi et al., 2003;
Voss et al., 2006), poly(I:C) is also a strong inducer of IL-1, IL-6, and TNF-
α (
Fortier et al., 2004b;
Traynor et al., 2004;
Gilmore et al., 2005). Our pilot data suggesting that IL-1
α, TNF-
α, and IFN
γ do not cause behavioral changes in the offspring may be surprising, because these cytokines induce IL-6
in vivo (
Gadient and Otten, 1997). However, high levels of maternal IL-6 are necessary for the behavioral changes we observe in the adult offspring, and it may be that these cytokines [as well as lower intraperitoneal doses of IL-6 or poly(I: C)] do not produce levels of IL-6 sufficient to have an effect on the fetus.
Although it is remarkable that a single intraperitoneal injection of IL-6 is capable of altering the fetal brain, leading to abnormal adult behavior, the cytokine stimulation by poly(I:C) is also quite transient. Poly(I:C)-treated mice display sickness behavior (lethargy, hunched posture, hindlimb stiffness), beginning ~30 min after injection and lasting ~6 h (data not shown), and a biphasic temperature response consisting of 4–8 h of hyperthermia followed by 12–24 h of hypothermia (
Traynor et al., 2004;
Cunningham et al., 2007). However, the effects of poly(I:C) treatment are mild compared with experimental influenza infection, in which sickness behavior and hypothermia last for several days (
Yang and Evans, 1961;
Shi et al., 2003). Previous work with pregnant rats demonstrated that three injections of IL-6 over 5 d caused increased latency to find the platform in the Morris water maze in the adult offspring (
Samuelsson et al., 2006). The total amount of IL-6 administered to the rats was similar to the total amount administered in our study, although the rats received the dose spread over 5 d. The offspring of the IL-6-injected rats also exhibited pyknotic cells similar to those reported in the offspring of rats given injections of poly(I:C) (
Zuckerman et al., 2003). This pathology is not, however, observed in the offspring of maternal poly(I:C)-treated mice (
Meyer et al., 2006) (and our data not shown). Early postnatal administration of epidermal growth factor or leukemia inhibitory factor over several days also cause PPI deficits, tested in adulthood (
Futamura et al., 2003;
Watanabe et al., 2004), but in none of these previous studies were the roles of endogenous cytokines examined.
Ideally, one would like to extend these cytokine-blocking experiments to the model of maternal infection with influenza virus (
Shi et al., 2003), because this model more closely recapitulates the human data related to mental illness. However, when pregnant C57 females are infected with influenza virus and given an anti-IL-6 injection, they become more severely ill than mice given saline injections and either die or suffer miscarriage (data not shown). Similar results were obtained with influenza infection of IL-6 KO mice (data not shown). A previous study on experimental influenza infection in nonpregnant IL-6 KO mice reported changes in weight loss, body temperature, and anorexia but did not report effects on survival (
Kozak et al., 1997). That study also only lasted for 5 d, and we do not see major differences until 6–7 d, when wild-type mice begin to recover and KO mice do not. The increased severity of infection in IL-6-compromised mice forced us to use the poly(I:C), pathogen-free MIA model for the IL-6 blocking experiments.
The observation that elimination of IL-6 in the MIA model almost completely abrogates abnormal behaviors and transcriptome changes in the offspring suggests that searches for other mediators of MIA should be directed upstream and downstream of IL-6, rather than in other signaling pathways. IL-6 is a pleiotropic cytokine that signals through heterodimerization of gp130 and IL-6 receptor (IL-6R) on the cell surface (
Bauer et al., 2007). However, most cells express gp130, and the soluble form of the IL-6R that is present in blood allows
trans signaling (
McLoughlin et al., 2005), which enables many cells to respond to IL-6. In considering the location of IL-6 action in the MIA model, three major sites of signaling seem likely: the maternal immune system, the maternal/fetal interface (i.e., the placenta), and the fetal brain.
The most obvious possibility is that IL-6 acts directly on the fetal brain. IL-6 is known to play a role in brain development, learning, and memory and in the CNS response to disease and injury (
Bauer et al., 2007). IL-6 is central to inflammation-induced working memory disruption (
Sparkman et al., 2006) and plays an important role in long-term potentiation in normal rats (
Balschun et al., 2004). During development, the STAT (signal transducers and activators of transcription) pathway, through which IL-6 signals, regulates the balance between neurogenesis and gliogenesis (
He et al., 2005) and IL-6 triggers brain endothelial cells to divide and migrate (
Yao et al., 2006). After injury, IL-6 can assume very different roles, triggering either neuronal survival or neuronal degeneration, through mechanisms that are not well understood (
Gadient and Otten, 1994;
Wagner, 1996;
Harry et al., 2006). Regarding access to the fetus, radiolabeled IL-6 can enter the rat fetus during mid, but not late, gestation (
Dahlgren et al., 2006), which correlates with human data showing influenza infection increases risk for schizophrenia only in the second trimester (
Brown, 2006). Elevated levels of cytokine protein and mRNA (including IL-6) have been detected in embryonic serum and brain after MIA (
Fidel et al., 1994;
Cai et al., 2000;
Urakubo et al., 2001;
Gayle et al., 2004;
Paintlia et al., 2004;
Gilmore et al., 2005;
Ashdown et al., 2006;
Beloosesky et al., 2006;
Meyer et al., 2006;
Xu et al., 2006). IL-6 can regulate brain-derived neurotrophic factor (BDNF) expression (
Murphy et al., 2000), and a decrease in BDNF is found in embryos and placentas 24 h after poly(I:C) administration (
Gilmore et al., 2005). Thus, although the pleiotropic nature of IL-6 makes it difficult to predict the precise mechanism of action in the brain, many plausible pathways exist.
A second target of interest is the placenta, because IL-6 could alter the transfer of nutrients, hormones, or other key molecules to the fetus. IL-6 alters vascular permeability in the adult brain after bacterial challenge (
Paul et al., 2003), and expression of genes responsible for the integrity of the placental barrier are decreased after MIA (
Beall et al., 2005). This could have significant effects on transfer of potentially harmful proteins (i.e., antibodies) into the fetal environment, or could allow maternal immune cells to infiltrate the fetus.
IL-6 could also act on the maternal immune system, activating lymphocyte migration and cytotoxicity and degrading maternal tolerance of the fetus. Normal pregnancy is characterized by a shift in basal cytokine production and other adjustments to prevent rejection of the fetus (
Sargent et al., 2006). Severe MIA causes loss of pregnancy in rodents, and depletion of uterine natural killer (uNK) cells prevents this loss, indicating that uNK cells mediate the effect (
Arad et al., 2005). IL-6 could also enhance production of maternal antibodies, which could cross-react with the fetal brain, as has been proposed to occur in autism (
Warren et al., 1990;
Dalton et al., 2003;
Vincent et al., 2003;
Singer et al., 2006;
Zimmerman et al., 2007). Future research on the mechanism of MIA effects on fetal brain development and on potential therapeutic approaches can therefore productively focus on the effects of IL-6 on the maternal–fetal unit.